| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2022 | SYNEDGEN, INC. | 1420 N CLAREMONT BLVD | CLAREMONT | CA | 91711-3583 | LOS ANGELES | USA | U01EY030406 | Identification of lead compounds to topically treat sulfur mustard injury to reduce ocular damage and improve vision. | 000 | 3 | NIH | 6/7/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $33,733 ) |
| | 2022 | 2022 | SYNEDGEN, INC. | 1420 N CLAREMONT BLVD STE 105D | CLAREMONT | CA | 91711-3583 | LOS ANGELES | USA | U01EY030406 | Identification of lead compounds to topically treat sulfur mustard injury to reduce ocular damage and improve vision. | 000 | 3 | NIH | 12/15/2021 | $33,733 |
|
| Issue Date FY: 2021 ( Subtotal = $319,250 ) |
| | 2021 | 2021 | SYNEDGEN, INC. | 1420 N CLAREMONT BLVD STE 105D | CLAREMONT | CA | 91711-3583 | LOS ANGELES | USA | U01EY030406 | Identification of lead compounds to topically treat sulfur mustard injury to reduce ocular damage and improve vision. | 000 | 3 | NIH | 8/2/2021 | $319,250 |
|
| Issue Date FY: 2020 ( Subtotal = $396,491 ) |
| | 2020 | 2020 | SYNEDGEN, INC. | 1420 N CLAREMONT BLVD STE 105D | CLAREMONT | CA | 91711-3583 | LOS ANGELES | USA | U01EY030406 | Identification of lead compounds to topically treat sulfur mustard injury to reduce ocular damage and improve vision. | 000 | 2 | NIH | 8/3/2020 | $321,965 |
| | 2020 | 2020 | SYNEDGEN, INC. | 1420 N CLAREMONT BLVD STE 105D | CLAREMONT | CA | 91711-3583 | LOS ANGELES | USA | U01EY030406 | Identification of lead compounds to topically treat sulfur mustard injury to reduce ocular damage and improve vision. | 001 | 2 | NIH | 8/27/2020 | $74,526 |
|
| Issue Date FY: 2019 ( Subtotal = $329,155 ) |
| | 2019 | 2019 | SYNEDGEN, INC. | 1420 N CLAREMONT BLVD STE 105D | CLAREMONT | CA | 91711-3583 | LOS ANGELES | USA | U01EY030406 | Identification of lead compounds to topically treat sulfur mustard injury to reduce ocular damage and improve vision. | 000 | 1 | NIH | 9/17/2019 | $329,155 |
| | 2019 | 2015 | SYNEDGEN, INC. | 1420 N CLAREMONT BLVD STE 105D | CLAREMONT | CA | 91711-3583 | LOS ANGELES | USA | R43DK107004 | Prevention and treatment of GI obstruction syndromes in cystic fibrosis | 000 | 1 | NIH | 6/24/2019 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $0 ) |
| | 2017 | 2016 | SYNEDGEN, INC. | 1420 N CLAREMONT BLVD STE 105D | CLAREMONT | CA | 91711-3583 | LOS ANGELES | USA | R43DK098847 | Novel treatment for Crohn's disease and related inflammatory gastrointestinal disease | 000 | 1 | NIH | 8/14/2017 | $0 |
| | 2017 | 2015 | SYNEDGEN, INC. | 1420 N CLAREMONT BLVD STE 105D | CLAREMONT | CA | 91711-3583 | LOS ANGELES | USA | R43DK107004 | Prevention and treatment of GI obstruction syndromes in cystic fibrosis | 000 | 1 | NIH | 8/7/2017 | $0 |
| | 2017 | 2012 | SYNEDGEN, INC. | 1420 N CLAREMONT BLVD STE 105D | CLAREMONT | CA | 91711-3583 | LOS ANGELES | USA | R44DE019740 | Antimicrobial and Regenerative Treatment for Oral Mucositis | 000 | 3 | NIH | 5/11/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $224,412 ) |
| | 2016 | 2016 | SYNEDGEN, INC | 1420 N Claremont Blvd 105d | Claremont | CA | 91711-3583 | LOS ANGELES | USA | R43DK098847 | Novel treatment for Crohn's disease and related inflammatory gastrointestinal disease | 000 | 1 | NIH | 4/19/2016 | $224,412 |
|
| Issue Date FY: 2015 ( Subtotal = $146,412 ) |
| | 2015 | 2015 | SYNEDGEN, INC | 1420 N Claremont Blvd 105d | Claremont | CA | 91711-3583 | LOS ANGELES | USA | R43DK107004 | Prevention and treatment of GI obstruction syndromes in cystic fibrosis | 000 | 1 | NIH | 7/14/2015 | $143,516 |
| | 2015 | 2015 | SYNEDGEN, INC | 1420 N Claremont Blvd 105d | Claremont | CA | 91711-3583 | LOS ANGELES | USA | R43DK107004 | Prevention and treatment of GI obstruction syndromes in cystic fibrosis | 001 | 1 | NIH | 8/7/2015 | $2,896 |
|
| Issue Date FY: 2013 ( Subtotal = $149,901 ) |
| | 2013 | 2013 | SYNEDGEN, INC | 1420 N Claremont Blvd 105d | Claremont | CA | 91711-3583 | LOS ANGELES | USA | R43HL118867 | MUCOLYTIC FOR ENHANCED MUCUS AND BIOFILM CLEARANCE IN CYSTIC FIBROSIS PATIENTS | 000 | 1 | NIH | 8/7/2013 | $149,901 |
|
| Issue Date FY: 2012 ( Subtotal = $970,980 ) |
| | 2012 | 2012 | SYNEDGEN, INC | 1420 N Claremont Blvd 105d | Claremont | CA | 91711-3583 | LOS ANGELES | USA | R44DE019740 | Antimicrobial and Regenerative Treatment for Oral Mucositis | 000 | 3 | NIH | 3/21/2012 | $970,980 |
|
| Issue Date FY: 2011 ( Subtotal = $992,846 ) |
| | 2011 | 2011 | SYNEDGEN, INC | 1420 N Claremont Blvd 105d | Claremont | CA | 91711-3583 | LOS ANGELES | USA | R44DE019740 | Antimicrobial and Regenerative Treatment for Oral Mucositis | 000 | 2 | NIH | 3/4/2011 | $868,268 |
| | 2011 | 2011 | SYNEDGEN, INC | 1420 N Claremont Blvd 105d | Claremont | CA | 91711-3583 | LOS ANGELES | USA | R44DE019740 | Antimicrobial and Regenerative Treatment for Oral Mucositis | 001 | 2 | NIH | 3/18/2011 | $124,578 |
|
| Issue Date FY: 2010 ( Subtotal = $99,638 ) |
| | 2010 | 2010 | SYNEDGEN, INC | 1420 N Claremont Blvd 105d | Claremont | CA | 91711-3583 | LOS ANGELES | USA | R43AI085684 | WOUND DECONTAMINATION FOR THE PREVENTION AND TREATMENT OF MULTI-DRUG RESISTANT BA | 000 | 1 | NIH | 2/25/2010 | $99,638 |
|
| Issue Date FY: 2009 ( Subtotal = $99,665 ) |
| | 2009 | 2009 | SYNEDGEN, INC | 1420 N Claremont Blvd 105d | Claremont | CA | 91711-3583 | LOS ANGELES | USA | R43DE019740 | PREVENTION AND TREATMENT OF ORAL BIOFILMS AND RELATED ORAL DISEASE BY SOLUBLE CHI | 000 | 1 | NIH | 9/11/2009 | $99,665 |
|
|
